# SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

> **NCT06743126** · PHASE3 · RECRUITING · sponsor: **Immatics US, Inc.** · enrollment: 360 (estimated)

## Conditions studied

- Melanoma, Cutaneous Malignant

## Interventions

- **BIOLOGICAL:** IMA203
- **BIOLOGICAL:** nivolumab plus relatlimab
- **BIOLOGICAL:** lifileucel
- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** pembrolizumab
- **BIOLOGICAL:** ipilimumab
- **DRUG:** Dacarbazine
- **DRUG:** temozolomide
- **DRUG:** paclitaxel
- **DRUG:** paclitaxel plus carboplatin
- **DRUG:** Albumin-Bound Paclitaxel

## Key facts

- **NCT ID:** NCT06743126
- **Lead sponsor:** Immatics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-14
- **Primary completion:** 2028-01
- **Final completion:** 2031-10
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06743126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06743126, "SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06743126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*